Welcome to our dedicated page for Silexion Therapeutics SEC filings (Ticker: SLXN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing Silexion’s filings can feel like decoding lab notes. Clinical data tables, RNA interference protocols, and financing footnotes sprawl across hundreds of pages, yet every detail may move the stock before the next trial read-out. If you have ever typed “Silexion SEC filings explained simply” or wondered whether the latest 8-K covered new KRAS results, you are not alone.
Stock Titan solves that problem. Our AI instantly converts dense disclosures into clear takeaways—highlighting cash runway, trial milestones, and partnership clauses—so you can focus on decisions, not document searches. Need to monitor “Silexion insider trading Form 4 transactions” or get a “Silexion quarterly earnings report 10-Q filing” the moment it hits EDGAR? We deliver real-time alerts and plain-English summaries, all in one place.
Here is what you will find on this page:
- “Silexion annual report 10-K simplified” to spot R&D spend and dilution risk.
- “Silexion Form 4 insider transactions real-time” tracking executive sentiment and option exercises.
- “Silexion proxy statement executive compensation” showing how management is rewarded for RNAi milestones.
- “Silexion 8-K material events explained” including clinical data releases or new Evonik agreements.
- “Silexion earnings report filing analysis” with AI-flagged shifts in trial timelines.
From “understanding Silexion SEC documents with AI” to catching a sudden “Silexion executive stock transactions Form 4,” every filing type is covered—10-K, 10-Q, 8-K, S-1, DEF 14A, and more—updated the second EDGAR posts. Spend less time untangling scientific jargon and more time evaluating whether SIL-204’s next data drop aligns with your investment thesis.
On July 16 2025 Silexion Therapeutics Corp ("SLXN") filed an 8-K announcing a 1-for-15 reverse share split affecting all issued, outstanding and authorized ordinary shares. The split will be effected automatically after market close on 28 Jul 2025, and the shares will begin trading on a split-adjusted basis on Nasdaq at the open on 29 Jul 2025; the ticker remains "SLXN".
- Every 15 existing shares convert into 1 new share.
- Par value increases from $0.0009 to $0.0135 per share.
- No fractional shares will be issued; DTC positions will be rounded up to the nearest whole share.
The Board’s goal is to raise the per-share price to maintain compliance with Nasdaq Capital Market listing standards. Warrants ("SLXNW") are expected to be adjusted pursuant to their terms. Additional details are provided in the press release attached as Exhibit 99.1.
Silexion Therapeutics Corp (NASDAQ: SLXN) filed a Form 8-K on 9 July 2025 under Item 7.01 (Regulation FD). The sole purpose of the filing is to furnish — not file — a press release (Exhibit 99.1) titled “Silexion Therapeutics Announces Positive Results in Preclinical Study Demonstrating Significant SIL204 Efficacy in Human Lung Cancer Cell Lines.” No additional financial statements or transaction details are included, and the company explicitly states the information is not incorporated by reference into other Securities Act filings.
Key points
- The press release reports positive preclinical efficacy for SIL204 in human lung cancer cell lines.
- The disclosure is furnished under Regulation FD, ensuring simultaneous public access to the information.
- No revenue, cost, guidance, or clinical-stage data accompany the announcement.
- Exhibits attached: 99.1 (press release) and 104 (Inline XBRL cover data).
Investors receive confirmation of encouraging scientific data but must consult Exhibit 99.1 for experimental specifics, as the 8-K itself contains minimal detail.
Silexion Therapeutics Corp (NASDAQ: SLXN) announced that a Nasdaq hearings panel has granted the company continued listing status, but with conditions. Effective July 8, 2025, the company’s ordinary shares and warrants will move from the Nasdaq Global Market to the Nasdaq Capital Market, keeping their current tickers “SLXN” and “SLXNW.”
The panel’s decision hinges on Silexion’s ability to achieve and maintain at least $2.5 million in shareholders’ equity by September 19, 2025 and to demonstrate that level in an SEC filing that includes a balance sheet dated within 60 days of submission. Nasdaq will retain jurisdiction over the company’s listing status until November 18, 2025; any further rule breaches before that date must be accompanied by an additional compliance plan for panel review.
Silexion also disclosed a potential bid-price deficiency (closing price below $1.00 for 30 consecutive trading days). Management intends to remedy this by executing a 1-for-15 reverse share split shortly after its reconvened annual general meeting on July 14, 2025, pending shareholder approval, with the split expected to take effect on or about July 25, 2025.
Key investor takeaway: Listing is preserved, but the company must raise equity or otherwise strengthen its balance sheet, complete the reverse split, and avoid additional rule breaches. Failure to meet these milestones could trigger delisting despite the current reprieve.
Silexion Therapeutics Corp (SLXN) filed a DEFA14A supplement to its previously issued definitive proxy statement for the 2025 annual general meeting (AGM). The only change disclosed is an updated shareholder record date: close of business on Tuesday, June 24, 2025, replacing the originally stated June 16, 2025. All other AGM details remain unchanged. The meeting will be held on July 7, 2025 at 9:00 a.m. ET / 4:00 p.m. Israel time at Meitar Law Offices in Ramat Gan, Israel, with an online attendance option that allows questions but does not permit remote voting. No financial metrics, earnings data, or transaction information were provided within this filing.
FAQ
What is the current stock price of Silexion Therapeutics (SLXN)?
What is the market cap of Silexion Therapeutics (SLXN)?
